Cargando…
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease
Current drugs used in the treatment of Parkinson's disease (PD), for example, L-DOPA and dopamine agonists, are very effective at reversing the motor symptoms of the disease. However, they do little to combat the underlying degeneration of dopaminergic neurones in the substantia nigra pars comp...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989582/ https://www.ncbi.nlm.nih.gov/pubmed/20735415 http://dx.doi.org/10.1111/j.1476-5381.2010.00882.x |